Choolip & Sciences츌립앤사이언스

Choolip & Sciences shares have risen sharply over the past year, but the company remains deeply loss-making with heavy borrowings.

Choolip & Sciences is a Korean biotech developing aptamer-based cancer drugs, with its lead candidate AST-201 in a Phase 1 trial in Korea. Its trailing twelve-month revenue is ₩5.4B against an operating loss of ₩8.6B, and it has ₩17.9B in cash versus ₩13.9B in borrowings. The data does not include a fair value estimate or analyst views.

What stands out

• Trailing twelve-month revenue is about ₩5.4B, while operating income is about -₩8.6B and net income about -₩11.7B, so losses are large relative to sales.
• Revenue grew strongly in 2024 and 2025 from a small base, reaching ₩3.5B in 2025, but operating losses have remained in the ₩7B to ₩12B range every year since 2021.
• Trailing free cash flow is about -₩12.0B, and liabilities are 62.2% of equity.
• The share price is up 35% over one month and 15.3% over one year, but it is still well below its 52-week high of about ₩4.0K. The price-to-book ratio is 1.8 and there is no meaningful earnings-based valuation because profits are negative.
• Recent filings include several 5%+ holding reports and insider shareholding reports dated 2026-08-20, plus a half-year report, two trading halts and a company name change notice in 2026.

What to watch

• The half-year report and any follow-up filings on how the company plans to fund its losses and debt, which the data does not detail.
• Clinical progress of AST-201 in its Phase 1 trial, which the data does not provide timing for.
• Further trading halts or changes in major shareholder holdings, since the recent filings include several of each and no news headlines are in the data.